Targeted Drug-Resistance Testing Strategy for Multidrug-Resistant Tuberculosis Detection, Lima, Peru, 2005–2008

Gustavo E. Velásquez, Martin Yagui, J. Peter Cegielski, Luis Asencios, Jaime Bayona, Cesar Bonilla, Hector O. Jave, Gloria Yale, Carmen Suárez, Sidney Atwood, Carmen C. Contreras, and Sonya S. Shin

The Peruvian National Tuberculosis Control Program issued guidelines in 2006 specifying criteria for culture and drug-susceptibility testing (DST), including district-level rapid DST. All patients referred for culture and DST in 2 districts of Lima, Peru, during January 2005–November 2008 were monitored prospectively. Of 1,846 patients, 1,241 (67.2%) had complete DST results for isoniazid and rifampin; 419 (33.8%) patients had multidrug-resistant (MDR) TB at the time of referral. Among patients with new smear-positive TB, household contact and suspected category I failure were associated with MDR TB, compared with concurrent regional surveillance data. Among previously treated patients with smear-positive TB, adult household contact, suspected category II failure, early relapse after category I, and multiple previous TB treatments were associated with MDR TB, compared with concurrent regional surveillance data. The proportion of MDR TB detected by using guidelines was higher than that detected by a concurrent national drug-resistance survey, indicating that the strategy effectively identified patients for DST.

Multidrug-resistant tuberculosis (MDR TB) is defined as infection with *Mycobacterium tuberculosis* with in vitro resistance to at least isoniazid and rifampin. The incidence of MDR TB disease was estimated to be 0.5 million in 2007, with a prevalence of as many as 2 million cases worldwide (1). Although no single best approach to MDR TB treatment has been recognized, rapid drug-susceptibility testing (DST) and prompt initiation of effective treatment are achievable goals. Ideally, treatment is based on timely, accurate DST, but if universal DST is not possible or not yet available, the national TB control program can prioritize patients at increased risk for MDR TB.

Rapid DST methods should minimize delays to initiation of appropriate treatment (2,3). Numerous assays have been developed that have characteristics suitable for use in low-income settings, including low cost, modest technical demand, and high accuracy (4–6). The nitrate reductase assay (NRA), also known as the Griess method, has demonstrated acceptable sensitivity, specificity, and speed compared with conventional DST and rapid phenotypic DST methods (7,8). This phenotypic assay was developed in Russia as a low-cost drug-susceptibility test that can be used in areas of moderate technical capacity (9). The method is based on a nitrate-reductase colorimetric reaction that uses Lowenstein-Jensen (LJ) medium prepared with antimicrobial drugs (9). Although initially validated as an indirect method, it was implemented as a direct method by the Peruvian National Institute of Health (INS) (10). The NRA yields drug-susceptibility information to isoniazid and rifampin 21–28 days after inoculating a smear-positive sputum sample (direct method) or 8–10 days after obtaining a positive culture (indirect method) (10). The pooled sensitivity and specificity of the NRA (on culture isolates and sputum) have been reported to be 97% and 100% for rifampin and 96% and 99% for isoniazid (11). The pooled sensitivity and specificity of direct NRA have been reported to be 99% and 100% for rifampin and...
94% and 100% for isoniazid (12). A recent comparison of 4 rapid DST methods with conventional DST in the context of a clinical trial suggested they may be cost-effective when compared with other health interventions (13). On the basis in part of these data, the World Health Organization (WHO) recently endorsed the use of NRA for screening patients at risk of MDR TB (14).

Despite the development of promising commercial and noncommercial rapid methods for MDR TB diagnosis, how to implement those methods under program conditions remains largely unaddressed. DST performance in validation studies differs greatly from performance integrated within a TB control program. Furthermore, the performance of any method under program conditions depends not only on assay characteristics, but also on the assets of the laboratory network and National Tuberculosis Control Program (NTP) guidelines which define criteria for performing DST.

To address this gap, we evaluated the effects of a programmatic strategy for rapid screening for MDR TB among risk groups specified by the Peruvian NTP in April 2006 (15). At that same time, decentralized, district-level MDR TB screening was pilot tested in 2 district laboratories in Lima, Peru. In collaboration with the Peruvian NTP and the Peruvian National Reference Laboratory (NRL), we evaluated the effectiveness of these combined strategies for detecting MDR TB. We report the proportion of drug resistance among risk groups based on screening high-risk patients as defined by explicit criteria, including rapid methods of DST in one of the first countries to implement this strategy.

Materials and Methods

Study Setting and Program Description

The prevalence of TB in Peru was 38,000 cases, and the incidence of TB in Peru was 126 cases/100,000 population per year, by 2007 estimates (16). The most recent national surveillance data indicate 5.3% of new TB cases and 24% of previously treated TB cases are MDR TB (16). In 1996, a collaborative effort to provide individualized treatment by using second-line drugs for MDR TB in northern Lima was established by Partners In Health, Socios En Salud, Harvard University, the Massachusetts State Laboratory Institute, the Peruvian NTP, and the Peruvian INS (4). In October 1997, the Peruvian NTP began a standardized treatment regimen including directly observed therapy with second-line drugs for patients in whom first-line drugs failed (17). Only 48% of these patients were treated successfully. During 2005 and 2006, the Peruvian INS and NTP transferred the capacity for DST to first-line TB drugs from the central level at the NRL to 2 district-level reference laboratories in Lima as a prelude to decentralizing these services to all major provinces (4). Simultaneously, the NTP issued national guidelines codifying criteria for MDR TB screening on the basis of known and suspected risk factors for MDR TB. In addition, these guidelines recommended the use of a more aggressive empiric MDR TB treatment regimen, including 5 second-line drugs for those persons with suspected MDR TB pending DST results. These programmatic and laboratory efforts resulted in an integrated strategy to diagnose and treat MDR TB cases in a timely and aggressive manner. During this period, we evaluated the effectiveness of selection criteria for DST in the first 2 laboratories (for health districts Lima Ciudad and Lima Este) where the NRA was implemented.

For persons in whom DST to first-line drugs confirmed drug resistance to isoniazid or rifampin, or both, the same isolate would be sent to the NRL for testing to a full panel of 5 first-line drugs and 5 second-line drugs. DST results were conveyed to health center providers by paper or electronic communication, and patients were evaluated with DST results to determine whether further regimen modification was needed (18). Details of treatment regimens have been described elsewhere (19). All patients diagnosed with TB were provided directly observed therapy free of charge through the NTP.

Study Patients and Enrollment Period

The patients enrolled in this cohort had suspected TB with respiratory symptoms living in 2 districts of Lima, Peru, Lima Ciudad or Lima Este, who met Peruvian NTP guidelines for DST referral as elaborated in Table 1. There were no exclusion criteria.

Enrollment Methods

Patients were identified by health care workers at their local health care establishments, and their sputum samples were sent to the reference laboratory for DST. Because all sputum samples for DST were sent to the district laboratories, subjects eligible for enrollment were identified by this referral. Study personnel visited each district laboratory on a regular basis to review sample referrals and confirm that all eligible subjects had been identified. Large, busy health centers were visited weekly and smaller, rural health centers were visited at least monthly for review of patient medical records. This method was used to confirm that all patients were included who were eligible without duplications. In Lima Ciudad, patients were enrolled from January 2005 through March 2008. In Lima Este, patients were enrolled from May 2005 through May 2008.

Drug Susceptibility Methods

The scale-up of MDR TB laboratory services in Peru, including expansion of the BACTEC-460 system (Becton, Dickinson and Company, Sparks, MD, USA) and NRA
(Griess) method for rapid first-line DST are described elsewhere \((4,5,20)\). The Peruvian NRL performed BACTEC-460 culture and DST on paucibacillary and smear-negative samples, prioritizing pediatric cases, HIV-positive persons, and health care workers. The scale-up of second-line conventional DST at the NRL by the indirect agar plate proportion method has also been described elsewhere \((4)\). The district reference laboratories cultured sputum specimens processed with 4% NaOH on Ogawa medium without centrifugation. During 2005, BioSafety Level 3 working conditions were established in 2 district reference laboratories, and these laboratories implemented DST on LJ medium for first-line drugs by using the indirect proportion method. Each procedure was validated by each laboratory through comparison with the Peruvian NRL and the Massachusetts State Laboratory Institute. Subsequently, the NRA was implemented in Lima Ciudad in December 2005 and in Lima Este in March 2007. The study spanned pre- and postintervention periods: January 2005 through November 2008 for Lima Ciudad and May 2005 through November 2008 for Lima Este. The NRA was used for rapid screening of smear-positive specimens from patients with the risk factors outlined in Table 1. Sputum specimens were processed with 2% NaOH/n-acetyl-L-cysteine, centrifuged at 3,000 × g, cultured on LJ medium, and simultaneously inoculated on modified LJ medium for the NRA to detect isoniazid and rifampin resistance.

Data Collection

A team of trained data recorders prospectively collected data using standardized forms. Sources of data included patient charts and laboratory registries and databases. HIV status was routinely recorded for TB patients. Available chest radiographs were reviewed by TB physicians who used standardized criteria to identify the type and location of radiographic abnormalities. Chest radiograph data were included if the radiograph was performed ≤1 year before the enrollment date or ≤1 month after the enrollment date. At baseline, clinical and sociodemographic data were recorded in addition to the risk factors outlined in Table 1. Data were entered into an Epi Info version 3.4.3 database (Centers for Disease Control and Prevention [CDC], Atlanta, GA, USA).

In addition to the data prospectively collected in this study, we used national and regional data from Peruvian NTP surveillance on drug resistance that were collected as part of the WHO Fourth Global Report on Anti-Tuberculosis Drug Resistance in the World \((21)\). Surveillance and laboratory methods are described in more detail in the WHO report \((21)\). For national data, we used all data in the NTP surveillance; for regional data, we included samples collected from health establishments served by the Lima Ciudad and Lima Este laboratories, which corresponded to the same catchment area as our study (Ministerio de Salud, unpub. data).

Patients were identified as having MDR TB if they had a positive culture for M. tuberculosis and DST results showed resistance to at least isoniazid and rifampin. Extensively drug-resistant TB was defined as resistance to at least isoniazid, rifampin, any fluoroquinolone, and >1 of 3 injectable second-line drugs (amikacin, capreomycin, or kanamycin). Monoresistance was defined as drug-resistance to isoniazid or rifampin, but not both drugs. Patients were considered to have drug-susceptible TB if their isolate was susceptible to both isoniazid and rifampin. Baseline refers to DST data at the time of referral, i.e., testing performed on sputum samples collected within 30 days of study enrollment. If baseline drug resistance data were not available for both isoniazid and rifampin (e.g., because of a culture-negative sample or because of contamination), the patient was considered to have no DST result.

Statistical Analysis

All analyses were performed by using STATA/IC version 10.1 (StataCorp LP, College Station, TX, USA). The χ² test or Fisher exact test was used to calculate p values, when appropriate. Point and interval estimation for the odds ratio were performed by using the Woolf procedure or the exact method, when appropriate. The Breslow-Day test for homogeneity was used to explore for effect modification. All statistical tests were 2-sided, and significance was set at α = 0.05.

Ethical Approval

The prospective observational cohort study providing data for this analysis was approved by institutional review boards at Brigham and Women’s Hospital and the Peruvian INS. An institutional review board amendment describing the aims of this analysis was approved by the Peruvian INS on October 15, 2008, and by the Partners Human Research Committee for Brigham and Women’s Hospital on September 23, 2008. This activity was approved by CDC as program evaluation and not as human subject research.

Results

A total of 1,846 patients were enrolled during the study period. Among these, 605 (32.8%) did not have baseline DST results, either due to a nonviable sample (99.2%) or incomplete resistance data for both isoniazid and rifampin (0.8%). The remaining 1,241 (67.2%) patients constitute the cohort for analysis presented here.

Of these 1,241, 419 (33.8%) had baseline MDR TB, among whom 195 (46.5%) had never been treated for TB and 224 (53.5%) had a history of previous TB treatment. Eight patients had extensively drug-resistant TB; 1 was a medical student, 1 had received prior self-administered
Clinically, they were less likely to have been tested by using the BACTEC-460 system and more likely to have hemoptysis. MDR TB patients and patients with drug-susceptible TB did not significantly differ with respect to their year of enrollment, gender, and history of TB treatment. Compared with patients with drug-susceptible TB, patients with monoresistant TB were younger and more likely to be single.

The most frequent risk factors prompting referral for DST among patients with new smear-positive TB were being adults with a household contact with known or suspected MDR TB (32.1%), diabetes mellitus (20.0%), and suspected category I failures (19.5%). Among previously treated patients with smear-positive TB, those with multiple (≥2) treatments (43.2%), adult household contact (18.6%), default of category I treatment (16.8%), and previously self-administered treatment (14.9%) were most frequently referred for DST. Among all patients with smear-positive TB, a single risk factor was identified in 485 (43.54%) patients, whereas 382 (34.29%), 205 (18.40%), 38 (3.41%), and 4 (0.36%) had 2, 3, 4, and 5 risk factors, respectively (data not shown).

The prevalence of MDR TB in Peru in 2007 among all TB patients, previously treated TB patients, and new TB patients is shown in Table 3 (21). In this national surveillance report, 8.3% of all TB patients, 5.2% of new TB patients, and 24.2% of previously treated TB patients in Peru were estimated to have MDR TB (21). Limiting surveillance data to the 2 districts where our cohort was enrolled, 12.4% of all TB patients, 9.9% of new TB patients, and 24.0% of previously treated TB patients had MDR TB (Ministerio de Salud, unpub. data). In our cohort of 1,241 subjects, 33.8% of all patients, 31.6% of new TB patients, and 35.8% of previously treated TB patients had MDR TB. Because national surveillance was conducted on smear-positive samples only, we compared the proportion of MDR TB among patients with smear-positive results in our cohort to prevalence of MDR TB from regional surveillance estimates. As shown in Tables 4 and 5, our cohort showed higher risk for MDR TB among new TB patients and previously treated TB patients.

When stratifying our cohort by risk group, we found that diabetes mellitus (16.8%), adult (33.5%) or child (53.9%) patients with household contacts with known or suspected MDR TB, and suspected category I failure, i.e., positive smear or culture during the second or third month of category I therapy (66.7%), were associated with significantly higher relative risks of MDR TB among patients with new smear-positive TB, when compared to regional surveillance prevalence estimates. Among the 18 patients with diabetes and new smear-positive MDR TB, 10 (55.6%) had 2 risk factors for MDR TB at the time of enrollment. Of these, 5 (27.8%) had suspected category I

---

**Table 1. Criteria for drug-susceptibility testing referral per Peruvian National Tuberculosis Control Program guidelines**

| A. Newly diagnosed smear- or culture-positive patients at risk for MDR TB. Persons were eligible for enrollment if they were 1) diagnosed with smear-positive pulmonary TB, 2) had no history of TB, and 3) had ≥1 of the following risk factors: |
|---|
| 1. Household contact of patient with documented MDR TB |
| 2. Household contact of patient in treatment with second-line drugs |
| 3. Household contact of patient who showed failure of TB therapy |
| 4. Household contact of patient who died of TB within the past 2 years |
| 5. HIV-positive by ELISA and Western blot confirmation |
| 6. Diabetes mellitus |
| 7. Health care worker, regardless of health care field, in the past 2 years |
| 8. Student of health sciences in the past 2 years |
| 9. Employee of the penitentiary system |
| 10. Chronic treatment with corticosteroids |
| 11. Other condition of immunosuppression |
| 12. Adverse reaction to TB medications requiring a change in regimen |
| 13. Hospitalization for any indication in the past 2 years lasting >15 days |

| B. Patients in whom first-line or second-line therapy may be failing. Persons were eligible for enrollment if they were 1) currently receiving first-line or second-line treatment, and 2) had a sputum sample collected after >2 months of treatment that was smear positive (i.e., monthly sputum collected between months 2 and 6) |
|---|
| 1. Households with previous TB patients and historically treated TB patients |
| 2. Relapsed after completion of any previous regimen within 6 months |
| 3. Unsuccessful treatment with any previous regimen |
| 4. Received multiple courses of TB treatment |
| 5. Had a history of private or auto-administered treatment |

| C. Patients who had received ≥1 previous treatment and who did not have documented MDR TB. This included persons who: |
|---|
| 1. Abandoned any previous regimen and now presented for retreatment |
| 2. Relapsed after completion of any previous regimen within 6 months |
| 3. Unsuccessful treatment with any previous regimen |
| 4. Received multiple courses of TB treatment |
| 5. Had a history of private or auto-administered treatment |

| D. Newly diagnosed smear-negative patients at risk for smear-negative MDR TB. Persons were eligible for enrollment if they were 1) suspected to have active pulmonary TB, 2) were smear negative, 3) had no history of TB therapy, and 4) had ≥1 of the following risk factors: |
|---|
| 1. Pediatric household contact of patient with documented MDR TB |
| 2. Pediatric household contact of patient who died of tuberculosis within the past 2 years |
| 3. HIV positive by ELISA and Western blot confirmation |

*MDR, multidrug resistant; TB, tuberculosis.
failure, 4 (22.2%) were adults with a household contact, and 1 (5.6%) had confirmed category I failure. Breslow-Day tests for homogeneity indicated that the effect of adult household contact on the odds of MDR TB is modified by diabetes (p<0.0001), and that the effect of suspected category I failure on the odds of MDR TB is modified by diabetes (p = 0.0113). One patient with new smear-positive TB was suspected of failing category II treatment (i.e., positive smear or culture during the second or third month of category II therapy); this same patient met the risk group criteria for adult household contact and private or self-administered treatment. Among previously treated patients with smear-positive TB, the following factors were significantly associated with a higher relative risk for MDR TB, compared with regional surveillance prevalence estimates: adult household contact (51.4%), failure of category I treatment (73.3%), early relapse after category I treatment (40.0%), suspected (84.6%) or confirmed (61.1%) failure of category II treatment, and history of ≥2 previous TB treatments (38.3%).

**Discussion**

We describe the proportion of drug resistance among TB patients as detected by using the screening strategy for MDR TB instituted in Lima, Peru, starting in 2005. When these data were compared with nearly concurrent population-based surveillance data, the proportion of MDR TB among new and previously treated TB cases was found to be significantly higher, indicating that screening high-risk patients may be an effective strategy. The proportion of MDR TB detected among patients with new smear-positive TB is comparable to that among previously treated patients with smear-positive TB in the cohort (p = 0.458). In the Peruvian NTP surveillance regional data corresponding to the study area, the prevalence of MDR TB among patients with new smear-positive TB was signficantly lower than the prevalence among previously treated patients with smear-positive TB (p<0.001). This finding shows that the strategy implemented in Lima was especially effective in detecting MDR TB among patients with new smear-positive TB.

The risk groups with the highest rates of MDR TB were those with diabetes mellitus, adults or children with...
household contacts with known or suspected TB, suspected failure of category I or II treatment (i.e., positive smear or culture during the second or third month of therapy), failure or early relapse to category I treatment, failure of category II treatment, and multiple (>2) previous TB treatments. Ample literature supports these findings in a variety of settings (22–25). Screening for drug resistance among these groups is easily implemented and should be strongly considered by national TB programs.

In addition to identifying risk groups with high prevalence of MDR TB, other considerations are pertinent to the design of an optimal programmatic strategy. For example, risk groups with a relatively low prevalence of MDR TB may still merit DST if delays in initiation of MDR TB treatment would have severe consequences (e.g., children or HIV-positive patients) or if the absolute number of MDR TB cases within that risk group is substantial (e.g., patients with diabetes). The relative complexity of implementing certain testing strategies is also a consideration. Compared with alternative testing strategies such as universal testing or testing by geographic region, a strategy that focuses on high-risk patients requires training health care workers to screen each TB patient for numerous risk factors. Therefore, case finding may be variable under routine program conditions.

Table 3. Prevalence estimates of TB drug resistance from national and regional surveillance data, and proportion of drug resistance in study cohort, Lima, Peru, 2005–2008*

| Cohort | Total no. patients | No. (%) susceptible to INH and RIF | No. (%) monoresistant to INH or RIF | No. (%) MDR TB |
|--------|-------------------|----------------------------------|----------------------------------|----------------|
| Peruvian NTP drug-resistance surveillance, national data (21) | | | | |
| All TB patients | 2,167 | 1,829 (84.4) | 158 (7.3) | 180 (8.3) |
| New TB patients | 1,816 | 1,597 (87.9) | 124 (6.8) | 95 (5.2) |
| Previously treated TB patients | 351 | 232 (66.1) | 34 (9.7) | 85 (24.2) |

| Peruvian NTP drug-resistance surveillance, regional data corresponding to study area† | | | | |
| All TB patients | 580 | 467 (80.5) | 41 (7.1) | 72 (12.4) |
| New TB patients | 476 | 396 (83.2) | 33 (6.9) | 47 (9.9) |
| Previously treated TB patients | 104 | 71 (68.3) | 8 (7.7) | 25 (24.0) |

| Study cohort | | | | |
| All TB patients | 1,241 | 661 (53.3) | 161 (13.0) | 419 (33.8) |
| New TB patients | 612 | 333 (54.4) | 84 (13.7) | 195 (31.9) |
| Previously treated TB patients | 629 | 328 (52.2) | 77 (12.2) | 224 (35.6) |

| Study cohort, smear-positive samples only | | | | |
| All TB patients | 1,114 | 581 (52.2) | 143 (12.8) | 390 (35.0) |
| New TB patients | 531 | 278 (52.4) | 73 (13.8) | 180 (33.9) |
| Previously treated TB patients | 583 | 303 (52.0) | 70 (12.0) | 210 (36.0) |

Table 4. MDR TB among new smear-positive TB patients compared with regional surveillance prevalence estimates, by NTP risk group, Lima, Peru, 2005–2008*

| Risk factor | Total no. patients | No. (%) MDR TB | Odds ratio (95% CI) |
|-------------|-------------------|----------------|-------------------|
| New smear-positive TB patients in NTP regional surveillance data | 476 | 47 (9.9) | 3.04 (0.06–38.63) |
| New smear-positive TB patients in study cohort | 531 | 180 (33.9) | 18.26 (11.01–30.26) |
| HIV positive | 46 | 8 (17.4) | 1.59 (0.53–4.79) |
| Diabetes mellitus | 107 | 18 (16.8) | 1.85 (1.62–3.33) |
| Chronic corticosteroid therapy | 4 | 0 | NA |
| Other immunosuppression | 5 | 0 | NA |
| Adverse reaction | 4 | 1 (25.0) | 3.04 (0.06–38.63) |
| Previous hospitalization within the past 2 y with duration >15 d | 5 | 2 (40.0) | 6.09 (0.49–514.5) |
| Health care worker during the past 2 y | 24 | 4 (16.7) | 1.83 (0.60–5.57) |
| Health sciences student during the past 2 y | 29 | 5 (17.2) | 1.90 (0.69–5.22) |
| Prisoner during the past 2 y | 27 | 4 (14.8) | 1.59 (0.53–4.79) |
| Adult patient with household contact risk factor(s)† | 170 | 57 (33.5) | 4.60 (2.97–7.14) |
| Pediatric patient with household contact risk factor(s)† | 13 | 7 (53.9) | 10.65 (2.90–39.71) |
| Private or self-administered treatment | 2 | 2 (100.0) | NA |
| Sputum positive during second or third month of category I treatment | 105 | 70 (66.7) | 18.26 (11.01–30.26) |
| Sputum positive during second or third month of category II treatment | 1 | 1 (100.0) | NA |

*MDR, multidrug resistant; TB, tuberculosis; NTP, National Tuberculosis Control Program; CI, confidence interval; NA, not applicable.
†Household contact risk factors are defined as household contact with a patient with known MDR TB, with a patient who showed TB treatment failure in the past 2 y, or with a patient being treated with second-line TB drugs.
The findings of this evaluation are subject to several limitations. Although our study personnel would visit local health establishments in a purely observational capacity, the frequent visits by data collectors in the health centers could have sensitized health workers to follow screening and referral protocols more closely than they would have otherwise. In addition, given the use of phenotypic methods, the drug-resistance status of particular isolates could be determined only for culture-positive samples. Although the yield of positive cultures was high for all methods used (67.4% for indirect conventional DST, 78.5% for direct NARA, and 35.3% for largely paucibacillary or smear-negative samples submitted for BACTEC; data not shown), the contribution to relative risk of MDR TB among those without DST results could not be determined. These results call attention to one of the shortcomings of all phenotypic methods, i.e., a substantial fraction of patients never have positive cultures or DST results to confirm the diagnosis or guide therapy, despite being at high risk for having MDR TB. Nonetheless, the yield of positive cultures in our sample is similar to that obtained by programs that have used the same sputum-processing methods (N-acetyl-L-cysteine and centrifugation, with cultivation on LJ medium). Finally, this evaluation was observational in nature and lacks a concurrent comparison group, such as one that had undergone an alternative screening strategy. On the other hand, this study has key strengths. The programmatic nature of this intervention, an active field presence to capture accurate and complete data on a large cohort, and the fortuitous concurrent surveillance study have allowed us to assess the effects of these programmatic efforts to identify patients with MDR TB.

To date, little research has been conducted on the comparative effectiveness of varied approaches to MDR TB screening and treatment referral. To our knowledge, the only study to show clinical results for performing rapid DST is a retrospective study carried out in California, which showed that using a molecular beacon assay led to earlier diagnosis and treatment initiation for MDR TB (26). An important aspect of program evaluation is feedback of findings to further improve treatment programs. In Peru, the results of this evaluation have been conveyed to the NTP and NRL. The aim of this communication is to describe an intensive evaluation of one of Peru’s public health strategies for improving MDR TB control. In other low- to middle-income countries, similar program evaluations should be implemented to clarify national and regional MDR TB epidemiology, identify key risk groups for MDR TB, and inform national strategies to diagnose and treat MDR TB. Ultimately, the effects of these changes

### Table 5. MDR TB among previously treated smear-positive TB patients compared with regional surveillance prevalence estimates, by NTP risk group, Lima, Peru, 2005–2008*

| Risk factor                                                                 | Total no. patients | No. (%) | Odds ratio (95% CI) |
|----------------------------------------------------------------------------|--------------------|---------|---------------------|
| Previously treated smear-positive TB patients in NTP regional surveillance data | 104                | 25 (24.0) |                     |
| Previously treated smear-positive TB patients in study cohort               | 583                | 210 (36.0) | 1.78 (1.10–2.88)    |
| HIV positive                                                               | 36                 | 12 (33.3)  | 1.58 (0.69–3.61)    |
| Diabetes mellitus                                                          | 30                 | 10 (33.3)  | 1.58 (0.65–3.82)    |
| Adverse reaction                                                           | 13                 | 1 (7.7)    | 0.26 (0.01–1.97)    |
| Previous hospitalization within the past 2 y with duration >15 d           | 4                  | 1 (25.0)   | 1.05 (0.02–13.80)   |
| Health care worker during the past 2 y                                     | 4                  | 1 (25.0)   | 1.05 (0.02–13.80)   |
| Health sciences student during the past 2 y                                | 4                  | 3 (75.0)   | 9.48 (0.71–503.7)   |
| Prisoner during the past 2 y                                               | 24                 | 4 (16.7)   | 0.63 (0.20–2.02)    |
| Adult case with household contact risk factor(s)†                          | 109                | 56 (51.4)  | 3.34 (1.86–6.00)    |
| Pediatric case with household contact risk factor(s)†                       | 7                  | 3 (42.9)   | 2.37 (0.32–14.92)   |
| Private or self-administered treatment                                     | 87                 | 28 (32.2)  | 1.50 (0.79–2.83)    |
| Sputum positive during second or third month of category I treatment        | 5                  | 3 (60.0)   | 4.74 (0.50–58.69)   |
| Sputum positive during second or third month of category II treatment       | 13                 | 11 (84.6)  | 17.38 (3.36–166.8)  |
| Failure of category I treatment‡                                           | 30                 | 22 (73.3)  | 8.69 (3.44–21.93)   |
| Relapsed within 6 mo after category I treatment§                           | 65                 | 26 (40.0)  | 2.11 (1.08–4.12)    |
| Defaulted while receiving category I treatment¶                             | 98                 | 15 (15.3)  | 0.57 (0.28–1.16)    |
| Failure of category II treatment‡                                          | 18                 | 11 (61.1)  | 4.97 (1.74–14.18)   |
| Relapsed within 6 mo after category II treatment¶                          | 8                  | 5 (62.5)   | 5.27 (0.93–35.66)   |
| Defaulted while receiving category II treatment¶                           | 63                 | 16 (25.4)  | 1.08 (0.52–2.22)    |
| Chronic treatment (>2 prior treatments)#                                   | 253                | 97 (38.3)  | 1.96 (1.17–3.29)    |

*MDR, multidrug resistant; TB, tuberculosis; CI, confidence interval; NTP, National Tuberculosis Control Program.
†Household contact risk factors are defined as household contact with a patient with known MDR TB, with a patient who showed TB treatment failure in the past 2 y, or with a patient being treated with second-line TB drugs.
‡Defined as positive smear and/or culture after >4 mo of treatment, or positive smear and/or culture upon finishing treatment.
§Defined as recurrence of disease <6 mo after being classified as cured by NTP norms.
¶Defined as not receiving treatment >1 mo upon enrollment into the study.
#Defined as a history of >2 previous TB treatments.
on turn-around time, time to culture conversion, cure rates, and costs will determine the comparative success of these strategies.

Acknowledgments

We thank Alex Sloutsky, Marsha Stowell, Lucy Vasquez, Neyda Quispe, Allison Taylor, and Joaquin Blaya for their meaningful contributions to the efforts described in this manuscript.

This study was supported by the Bill and Melinda Gates Foundation, the Centers for Disease Control and Prevention, and the United States National Institute of Allergy and Infectious Diseases. S.S.S. received partial salary support or travel support from the Bill and Melinda Gates Foundation, the Eli Lilly Foundation, the Frank Hatch Fellowships in Global Health Equity at the Brigham and Women’s Hospital, the Infectious Disease Society of America, the Heiser Foundation, and the United States National Institutes of Health.

Dr Velásquez is in his second postgraduate year of the Doris and Howard Hiatt Residency in Global Health Equity and Internal Medicine at Brigham and Women’s Hospital in Boston, Massachusetts. His research interests focus on TB and its management in resource-poor settings.

References

1. World Health Organization. Global tuberculosis control: a short update to the 2009 report [cited 2010 Jun 5]. http://www.who.int/tb/publications/global_report/2009/update/en/index.html
2. Yagui M, Perales MT, Asencios L, Vergara L, Suarez C, Yale G, et al. Timely diagnosis of MDR-TB under program conditions: is rapid drug susceptibility testing sufficient? Int J Tuberc Lung Dis. 2006;10:838–43.
3. Mitnick CD, Appleton SC, Shin SS. Epidemiology and treatment of multidrug resistant tuberculosis. Semin Respir Crit Care Med. 2008;29:499–524. DOI: 10.1055/s-0028-1085702
4. Shin SS, Yagui M, Asencios L, Yale G, Suarez C, Quispe N, et al. Scale-up of multidrug-resistant tuberculosis laboratory services, Peru. Emerg Infect Dis. 2008;14:701–8. DOI: 10.3201/ eid1405.070721
5. Asencios L, Yale G, Yagui M, Quispe N, Taylor A, Blaya J, et al. Programmatic implementation of rapid DST for Mycobacterium tuberculosis in Peru. Int J Tuberc Lung Dis. 2012;16:743–9.
6. Palomino JC. Nonconventional and new methods in the diagnosis of tuberculosis: feasibility and applicability in the field. Eur Respir J. 2005;26:339–50. DOI: 10.1183/09031936.05.00050305
7. Montoro E, Lemus D, Echemendia M, Martin A, Portaels F, Palomino JC. Comparative evaluation of the nitrate reduction assay, the MTT test, and the resazurin microtiter assay for drug susceptibility testing of clinical isolates of Mycobacterium tuberculosis. J Antimicrob Chemother. 2005;55:500–5. DOI: 10.1093/jac/dki023
8. Bwanga F, Joloba ML, Haile M, Hoffner S. Evaluation of seven tests for the rapid detection of multidrug-resistant tuberculosis in Uganda. Int J Tuberc Lung Dis. 2010;14:890–5.
9. Angeby KA, Klintz L, Hoffner SE. Rapid and inexpensive drug susceptibility testing of Mycobacterium tuberculosis with a nitrate reductase assay. J Clin Microbiol. 2002;40:553–5. DOI: 10.1128/JCM.40.2.553-555.2002
10. Solis LA, Shin SS, Han LL, Llanos F, Stowell M, Sloutsky A. Validation of a rapid method for detection of M. tuberculosis resistance to isoniazid and rifampin in Lima, Peru. Int J Tuberc Lung Dis. 2005;9:760–4.
11. Martin A, Panaioiotou S, Portaels F, Hoffner S, Palomino JC, Angeby K. The nitrate reductase assay for the rapid detection of isoniazid and rifampin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. J Antimicrob Chemother. 2008;62:56–64. DOI: 10.1093/jac/dkn139
12. Bwanga F, Hoffner S, Haile M, Joloba ML. Direct susceptibility testing for multi drug resistant tuberculosis: a meta-analysis. BMC Infect Dis. 2009;9:67. DOI: 10.1186/1471-2334-9-67
13. Acuna-Villaorduna C, Vassall A, Henostroza G, Seas C, Guerra H, Vasquez L, et al. Cost-effectiveness analysis of introduction of rapid, alternative methods to identify multidrug-resistant tuberculosis in middle-income countries. Clin Infect Dis. 2008;47:487–95. DOI: 10.1086/590010
14. World Health Organization. Non-commercial culture and drug-susceptibility testing methods for screening of patients at risk of multidrug resistant tuberculosis. 2010 Jul [cited 2011 Jan 20]. http://www.who.int/tb/laboratory/whopolicy_noncommercialculture_and_dst_methods_july10_revnov10.pdf
15. Ministerio de Salud. Norma técnica de salud para el control de la tuberculosis. Lima (Peru): Ministerio de Salud; 2006.
16. WorldHealthOrganization. TB country profile: Peru[cited 2010 Jun 5]. http://www.who.int/GlobalAtlas/predefinedReports/TB_PDF_Files/ per.pdf
17. Suárez PG, Floyd K, Portocarrero J, Alarcon E, Rapiti E, Ramos G, et al. Feasibility and cost-effectiveness of standardized second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet. 2002;359:1980–9. DOI: 10.1016/S0140-6736(02)08830-X
18. Blaya JA, Shin SS, Yagui MJ, Yale G, Suarez CZ, Asencios LL, et al. A web-based laboratory information system to improve quality of care of tuberculosis patients in Peru: functional requirements, implementation and usage statistics. BMC Med Inform Decis Mak. 2007;7:33. DOI: 10.1186/1472-6947-7-33
19. Mitnick C, Bayona J, Palacios E, Shin S, Furin J, Aleartana F, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med. 2003;348:1189–28. DOI: 10.1056/NEJMoa022928
20. Roberts GD, Goodman NL, Heifets L, Harsh HW, Lindner TH, McClethy JK, et al. Evaluation of the BACTEC radiometric method for recovery of mycobacteria and drug susceptibility testing of Mycobacterium tuberculosis from acid-fast smear-positive specimens. J Clin Microbiol. 1983;18:689–96.
21. World Health Organization. Anti-tuberculosis drug resistance in the world. Fourth Global Report. The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance: 2002–2007 [cited 2010 Jun 17]. http://www.who.int/entity/tb/publications/2008/drs_report4_26feb08.pdf
22. Bashar M, Alcubes P, Rom WN, Condos R. Increased incidence of multidrug-resistant tuberculosis in diabetic patients on the Bellevue Chest Service, 1987 to 1997. Chest. 2001;120:1514–9. DOI: 10.1378/chest.120.5.1514
23. Fisher-Hoch SP, Whitney E, McCormick JB, Crespo G, Smith B, Rabhar MB, et al. Type 2 diabetes and multidrug-resistant tuberculosis. Scand J Infect Dis. 2008;40:888–93. DOI: 10.1080/00365540802342372
24. Teixeira L, Perkins MD, Johnson JL, Keller R, Palaci M, do Valle Dettoni V, et al. Infection and disease among household contacts of patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2001;5:321–8.
25. Becerra MC, Freeman J, Bayona J, Shin SS, Kim JY, Furin JJ, et al. Using treatment failure under effective directly observed short-course chemotherapy programs to identify patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2000;4:108–14.

26. Banerjee R, Allen J, Lin SY, Westenhouse J, Desmond E, Schacter GF, et al. Rapid drug susceptibility testing with a molecular beacon assay is associated with earlier diagnosis and treatment of multidrug-resistant tuberculosis in California. J Clin Microbiol. 2010;48(10):3779-81. Epub 2010 Aug 11.

Address for correspondence: Sonya S. Shin, Division of Global Health Equity, Brigham and Women’s Hospital, FXB Bldg, 7th Floor, 651 Huntington Ave, Boston, MA 02115, USA; email: sshin@partners.org

The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the Centers for Disease Control and Prevention or the institutions with which the authors are affiliated.

Visit www.cdc.gov/MRSA or call 1-800-CDC-INFO (800-232-4636)
TTY: (888) 232-6348 to order provider materials including:

> Clinician guidelines
> Evaluation & treatment recommendations
> Patient education materials
> Posters
> Fact sheets
> Flyers

cdcinfo@cdc.gov

Developed with support from the CDC Foundation through an educational grant from Pfizer Inc.